Expanding our research focus, we are targeting unmet needs in immune diseases including atopic dermatitis, rheumatoid arthritis, asthma, nasal polyposis, and eosinophilic esophagitis.
Immunology is an area of growth for us, and an area in which we hope to make a significant difference in patients’ lives. In collaboration with Regeneron, we currently have two therapies on the market and are researching and developing several new therapeutic areas.
The first therapy, approved in the U.S. and Europe, is indicated for adults with inadequately controlled moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease and the most common form of eczema. A second therapy, approved in the U.S., Canada, and Europe, is indicated for adults with moderate to severe rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints.
We are also studying other allergic and respiratory diseases, including asthma, nasal polyposis, and eosinophilic esophagitis.
Inspired by patients around the world
Above from left to right: Catherine, rheumatoid arthritis, USA; Hilde, atopic dermatitis, Norway; Vergard, atopic dermatitis, Norway